Joe Walker work email
- Valid
- Valid
Joe Walker personal email
- Valid
Joe Walker phone numbers
Responsible/Accountable for all aspects of development of the assets in the BMS neuroscience portfolio. A Leader of Leaders.Leader of cross-functional matrixed development teams...including clinical, commercial, CMC, regulatory, clinical pharmacology, translational & biomarkers, clinical operations, toxicology, DM-PK, VAP/pricing, etc.Select Publications:Mega JL, Walker JR, Ruff CT, Vandell A, et al. “Genetics and the Clinical Response to Warfarin and Edoxaban” Lancet 2015; 385 (9984): 2280–2287.Mega J, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker J, Antman E, Macias W, Braunwald E, Sabatine M. “Cytochrome P450 Polymorphisms and the Pharmacologic and Clinical Response to Clopidogrel” New England Journal of Medicine 2009; 360(4):354-62.Walker JR, Brown K, Rohatagi S, Bathala MS, Xu C, Wickremasingha PK, Salazar DE, Mager DE. “Quantitative Structure-Property Relationships Modeling to Predict In Vitro and In Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol)” Journal of Clinical Pharmacology 2009; 49(10):1185-95.[Winner of 2010 McKeen Cattell Memorial Award for outstanding manuscript in the Journal of Clinical Pharmacology]Specific technical experience designing early clinical development strategies, companion diagnostic strategies, clinical pharmacology strategies, and personalization strategies; leading clinical pharmacology studies; and selection and validation of biomarkers within the diabetes, thrombosis, and oncology areas.Specialties: Global Program LeadershipEarly Drug DevelopmentNeuroscience, Neurology, NeurodegenerationAlzheimer's Disease, Multiple SclerosisMonoclonal antibodiesT Cell Engaging Bispecific antibodiesImmuno-oncologyCompanion Diagnostics (CDx) PharmacogenomicsClinical PharmacologyPersonalized MedicineProject Leadership
-
Vice President & Sr Global Program Leader - NeuroscienceBristol Myers Squibb Nov 2021 - Mar 2024Lawrence Township, Nj, Us -
Executive Director & Senior Early Development Program Lead, NeuroscienceBristol Myers Squibb Nov 2019 - Jan 2022Lawrence Township, Nj, UsLeader for Early Development of the neuroscience portfolio. (BMS acquired Celgene in 2019.)
-
Executive Director, Global Project LeadershipCelgene Sep 2014 - Nov 2019Summit, New Jersey, UsLed large global cross-functional drug development teams (which include clinical, nonclinical, CMC, regulatory, translational, commercial, project management, et al). Directly accountable to executive governance for overall vision, development strategy and execution from candidate nomination through IND / first-in-human to clinical proof of concept. Global Program Lead for CC-93269 (BCMA x CD3 bispecific antibody), CC-90002 (CD47 antibody), CC-94676 (Androgen Receptor Ligand-Directed Degrader), and CC-90003 (small molecule ERK inhibitor). Specific interest in model-based drug development and innovative drug development techniques. -
Senior Director, Companion Diagnostics & PharmacogenomicsDaiichi Sankyo Feb 2012 - Sep 2014Basking Ridge, Nj, UsResponsible for development, registration, and commercialization of companion diagnostics to accompany our therapeutic productsResponsible for strategic PGx activities across all therapeutic areas -
Director, Clinical Pharmacology, Oncology & PharmacogenomicsDaiichi Sankyo Apr 2006 - Feb 2012Basking Ridge, Nj, UsResponsible for creation and execution of innovative early clinical development strategies (FIH --> PoC). The goal is to efficiently clarify the major in vivo properties of a drug candidate in order to support early Go/No-Go decisions. Developed and executed the clinical pharmacology components of a clinical development plan at all stages of development in order to support dose selection, formulation selection, appropriate use of the drug, labeling, and registration. Developed and executed clinical pharmacogenomic and biomarker research plans that support drug differentiation and personalization strategies.
-
Manager, Clinical Pharmacology & PharmacokineticsDaiichi Sankyo Aug 2003 - Apr 2006Basking Ridge, Nj, Us
-
Associate Director, PharmacogenomicsOrchid Cellmark Jul 2000 - Aug 2003Orchid GeneShield - an innovative personalized medicine company.Lead efforts to create an ADR (adverse drug reaction) risk assessment tool using PGx and EMR (electronic medical records) data. This was an early forerunner of the current 'consumer genetics' products such as '23 and me', Navigenics, deCodeMe, etc.Conducted Clinical Pharmacology studies to evaluate PGx effects on drug response (safety, efficacy, PK/PD)
Joe Walker Education Details
-
University Of FloridaPost-Doctoral Fellowship -
Emory UniversityResidency
-
University Of TennesseePharmd
Frequently Asked Questions about Joe Walker
What is Joe Walker's role at the current company?
Joe Walker's current role is Former VP at BMS/Celgene. Early Drug Development Leader.
What is Joe Walker's email address?
Joe Walker's email address is wa****@****hoo.com
What is Joe Walker's direct phone number?
Joe Walker's direct phone number is (858)-558*****
What schools did Joe Walker attend?
Joe Walker attended University Of Florida, Emory University, University Of Tennessee.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial